The Medical Advisor

Medically Reviewed | Last Updated on June 30, 2026 This article discusses dosage considerations and key factors related to the use of ivermectin in cancer treatment. Much of the publicly available information regarding ivermectin dosage is based on the standard dosing recommendations developed by Merck for the treatment of parasitic infections. These dosages are often cited without distinction from the higher or alternative dosing regimens that have been explored in cancer-related research. Dosages used for parasitic infections may not correspond to those investigated in oncology studies. Potential dosing strategies may vary depending on several factors, including the patient's body weight, cancer type, cancer stage and grade, overall health status, and liver function. When estimating an ivermectin dosage for cancer-related purposes, multiple ...

Medically Reviewed by: OneDayMD Editorial Team | Last Updated: June 2026 Abstract Background: Repurposed antiparasitic agents, including ivermectin and benzimidazoles (fenbendazole and mebendazole), have gained attention for their potential anticancer properties, particularly in colorectal cancer. Preclinical studies suggest these agents may exert antitumor effects through mechanisms such as inhibition of cell proliferation and disruption of key oncogenic pathways, including Wnt/β-catenin signaling. Objective: To summarize and evaluate a compilation of case reports describing the use of ivermectin and benzimidazole-based regimens in patients with colorectal cancer, with a focus on advanced-stage disease. Methods: This review analyzes a curated series of 80+ case reports involving patients with colorectal or related gastrointestinal cancers treated with ivermectin in combination with fenbendazole or mebendazole, often alongside standard therapies such as chemotherapy. Reported out...